An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
29 11 2019
Historique:
received: 11 04 2019
accepted: 15 10 2019
entrez: 1 12 2019
pubmed: 1 12 2019
medline: 11 3 2020
Statut: epublish

Résumé

Assessment of tumor infiltrating lymphocytes (TILs) as a prognostic variable in melanoma has not seen broad adoption due to lack of standardization. Automation could represent a solution. Here, using open source software, we build an algorithm for image-based automated assessment of TILs on hematoxylin-eosin stained sections in melanoma. Using a retrospective collection of 641 melanoma patients comprising four independent cohorts; one training set (N = 227) and three validation cohorts (N = 137, N = 201, N = 76) from 2 institutions, we show that the automated TIL scoring algorithm separates patients into favorable and poor prognosis cohorts, where higher TILs scores were associated with favorable prognosis. In multivariable analyses, automated TIL scores show an independent association with disease-specific overall survival. Therefore, the open source, automated TIL scoring is an independent prognostic marker in melanoma. With further study, we believe that this algorithm could be useful to define a subset of patients that could potentially be spared immunotherapy.

Identifiants

pubmed: 31784511
doi: 10.1038/s41467-019-13043-2
pii: 10.1038/s41467-019-13043-2
pmc: PMC6884485
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5440

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : P30CA016359
Pays : International
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : KL2TR001874
Pays : International

Références

J Natl Cancer Inst. 1989 Dec 20;81(24):1893-904
pubmed: 2593166
Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25
pubmed: 29024776
J Clin Oncol. 2013 Nov 20;31(33):4252-9
pubmed: 24127443
J Clin Oncol. 2010 Oct 10;28(29):4531-8
pubmed: 20516428
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Clin Cancer Res. 2004 Nov 1;10(21):7252-9
pubmed: 15534099
Nat Rev Cancer. 2014 Feb;14(2):135-46
pubmed: 24457417
J Clin Oncol. 2012 Jul 20;30(21):2678-83
pubmed: 22711850
Acta Pathol Microbiol Scand A. 1978 Nov;86A(6):523-30
pubmed: 716913
J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4
pubmed: 16106022
Semin Cancer Biol. 2018 Oct;52(Pt 2):151-157
pubmed: 29990622
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Sci Rep. 2012;2:503
pubmed: 22787560
Am J Clin Pathol. 2001 Jun;115(6):856-60
pubmed: 11392882
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
J Natl Cancer Inst. 2018 Feb 1;110(2):
pubmed: 28859291
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Diagn Pathol. 2013 Feb 27;8:34
pubmed: 23445542
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
Mod Pathol. 2016 Oct;29(10):1155-64
pubmed: 27363491
Clin Cancer Res. 2019 Apr 15;25(8):2442-2449
pubmed: 30617133
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Cytometry. 1997 Aug 1;28(4):289-97
pubmed: 9266748
Cancer. 1996 Apr 1;77(7):1303-10
pubmed: 8608507
J Immunother Cancer. 2016 Nov 15;4:76
pubmed: 27895917

Auteurs

Balazs Acs (B)

Department of Pathology, Yale School of Medicine, New Haven, CT, 06510, USA.
Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

Fahad Shabbir Ahmed (FS)

Department of Pathology, Yale School of Medicine, New Haven, CT, 06510, USA.

Swati Gupta (S)

Department of Pathology, Yale School of Medicine, New Haven, CT, 06510, USA.

Pok Fai Wong (PF)

Department of Pathology, Yale School of Medicine, New Haven, CT, 06510, USA.

Robyn D Gartrell (RD)

Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center/New York Presbyterian, New York, NY, USA.

Jaya Sarin Pradhan (J)

Department of Pathology and Cell Biology, Division of Oral and Maxillofacial Pathology, Columbia University Irving Medical Center/New York Presbyterian, New York, NY, USA.

Emanuelle M Rizk (EM)

Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center/New York Presbyterian, New York, NY, USA.

Bonnie Gould Rothberg (B)

Department of Medicine, Yale School of Medicine, New Haven, CT, 06510, USA.

Yvonne M Saenger (YM)

Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center/New York Presbyterian, New York, NY, USA.

David L Rimm (DL)

Department of Pathology, Yale School of Medicine, New Haven, CT, 06510, USA. david.rimm@yale.edu.
Department of Medicine, Yale School of Medicine, New Haven, CT, 06510, USA. david.rimm@yale.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH